Brief: Daiichi Sankyo Says ENHERTU Gets U.S. Priority Review For HER2‑Positive Early Breast Cancer
09/03/2026 07:33
March 9 (Reuters) - Daiichi Sankyo Co Ltd 4568.T: ENHERTU® GRANTED PRIORITY REVIEW IN THE U.S. AS POST-NEOADJUVANT TREATMENT FOR PATIENTS WITH HER2 POSITIVE EARLY BREAST CANCER DAIICHI SANKYO CO LTD - FDA TARGET ACTION DATE FOR REGULATORY DECISION ON ENHERTU IS JULY 7, 2026 Source text: ID:nBw14VXsca Further company coverage: 4568.T (((( Reuters.Briefs@thomsonreuters.com ;));))